$ADHD to Present at Two CNS Focused Conferences in April


Alcobra Ltd. to Present at Two CNS Focused Conferences in April

TEL AVIV, Israel, April 6, 2015 (GLOBE NEWSWIRE) — Alcobra Ltd. (ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced that corporate presentations will be provided at two conferences focused on Central Nervous System (CNS) disorders in April.

10th Annual Neurotech Investing & Partnering Conference
Date: Tuesday, April 7
Time: 3:30pm Pacific Time
Location: Hotel Nikko, San Francisco
Presenter: David Baker, Chief Commercial Officer
Conference Information: www.neurotechconf.com
Neurology Innovation Conference
Date: Sunday, April 19
Time: 3:30pm Eastern Time
Location: Embassy Suites, Washington DC
Presenter: Jonathan Rubin, MD, MBA, Chief Medical Officer
Conference Information: www.neurologyinnovation.com

About Alcobra Ltd.

Alcobra Ltd. is an emerging pharmaceutical company primarily focused on the development and commercialization of a proprietary drug candidate, MDX, to treat cognitive disorders including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome. MDX has completed multiple Phase II studies and a Phase III study in adults with ADHD. The company is conducting separate Phase II trials in pediatric ADHD and in Fragile X Syndrome. For more information please visit the Company’s website, www.alcobra-pharma.com, the content of which is not incorporated herein by reference.

U.S. Investor Contacts
LifeSci Advisors, LLC
Michael Rice
Media Inquiries
Sam Brown, Inc.
Mike Beyer
Israel Investor Contact:
Alcobra Investor Relations
Debbie Kaye
+972-72 2204661


Please enter your comment!
Please enter your name here